These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 34452358)

  • 1. Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases.
    Alhashimi M; Elkashif A; Sayedahmed EE; Mittal SK
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral vector immunity: its implications and circumvention strategies.
    Ahi YS; Bangari DS; Mittal SK
    Curr Gene Ther; 2011 Aug; 11(4):307-20. PubMed ID: 21453277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of nonhuman adenoviruses as vaccine vectors.
    Bangari DS; Mittal SK
    Vaccine; 2006 Feb; 24(7):849-62. PubMed ID: 16297508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus vector-based vaccine for infectious diseases.
    Sakurai F; Tachibana M; Mizuguchi H
    Drug Metab Pharmacokinet; 2022 Feb; 42():100432. PubMed ID: 34974335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current strategies and future directions for eluding adenoviral vector immunity.
    Bangari DS; Mittal SK
    Curr Gene Ther; 2006 Apr; 6(2):215-26. PubMed ID: 16611043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.
    Coughlan L
    Front Immunol; 2020; 11():909. PubMed ID: 32508823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to overcome host immunity to adenovirus vectors in vaccine development.
    Thacker EE; Timares L; Matthews QL
    Expert Rev Vaccines; 2009 Jun; 8(6):761-77. PubMed ID: 19485756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
    Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
    Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.
    Hartman ZC; Appledorn DM; Amalfitano A
    Virus Res; 2008 Mar; 132(1-2):1-14. PubMed ID: 18036698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy.
    Wang WC; Sayedahmed EE; Mittal SK
    Viruses; 2022 Dec; 14(12):. PubMed ID: 36560730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model.
    Sharma A; Bangari DS; Tandon M; Hogenesch H; Mittal SK
    Virus Res; 2010 Oct; 153(1):134-42. PubMed ID: 20659505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen.
    Sheerin D; Dold C; O'Connor D; Pollard AJ; Rollier CS
    BMC Genomics; 2021 Oct; 22(1):777. PubMed ID: 34717548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunodominance of Adenovirus-Derived CD8
    Schöne D; Hrycak CP; Windmann S; Lapuente D; Dittmer U; Tenbusch M; Bayer W
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane.
    Vitelli A; Folgori A; Scarselli E; Colloca S; Capone S; Nicosia A
    Expert Rev Vaccines; 2017 Dec; 16(12):1241-1252. PubMed ID: 29047309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity.
    Maier C; Fuchs J; Irrgang P; Wißing MH; Beyerlein J; Tenbusch M; Lapuente D
    Front Immunol; 2022; 13():920256. PubMed ID: 36003372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.
    Singh N; Pandey A; Jayashankar L; Mittal SK
    Mol Ther; 2008 May; 16(5):965-71. PubMed ID: 18301400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
    Hrycak CP; Windmann S; Bayer W
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.
    Lopez-Gordo E; Podgorski II; Downes N; Alemany R
    Hum Gene Ther; 2014 Apr; 25(4):285-300. PubMed ID: 24499174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an adenovirus vector vaccine platform for targeting dendritic cells.
    Sharma PK; Dmitriev IP; Kashentseva EA; Raes G; Li L; Kim SW; Lu ZH; Arbeit JM; Fleming TP; Kaliberov SA; Goedegebuure SP; Curiel DT; Gillanders WE
    Cancer Gene Ther; 2018 Feb; 25(1-2):27-38. PubMed ID: 29242639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.
    Ewer K; Sebastian S; Spencer AJ; Gilbert S; Hill AVS; Lambe T
    Hum Vaccin Immunother; 2017 Dec; 13(12):3020-3032. PubMed ID: 29083948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.